Pfenex (PFNX) Tops Q4 EPS by 13c, Revenues Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/13/2026

1. MIRM
2. META
3. SPY
4. MSFT
5. JNJ
6. PLTR
7. LDOS
8. AXP
9. TMUS
10. AON

Go back to Pfenex (PFNX) Tops Q4 EPS by 13c, Revenues Miss

Pfenex Reports Fourth Quarter and Full Year 2018 Results and Provides Business Update

March 11, 2019 4:05 PM EDT

We believe PF708 is on track to enter the U.S. market as early as Q4 2019, subject to FDA approval and other factors

Several significant milestones across the Companys pipeline are expected in 2019

SAN DIEGO, March 11, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) is a clinical-stage development and licensing biotechnology company focused on leveraging its Pfnex Expression Technology® to develop and improve protein therapies for unmet patient needs. Using the patented Pfnex Expression Technology platform, the Company has created an advanced pipeline... More